Connecticut Statutes
§ 32-41jj — (Formerly Sec. 19a-32d). Regenerative medicine research: Definitions. Prohibition on human cloning. Disposition of embryos or embryonic stem cells following infertility treatment. Written consent required for donations. Embryonic stem cell research authorized. Penalties.
Connecticut·Title 32 Commerce and Economic and Community Development·Ch. 581 Innovation Capital Act of 1989. Connecticut Innovations, Incorporated
(a)As used in sections 32-41jj to 32-41mm, inclusive, and section 4-28e:
(1)“Embryonic stem cell research oversight committee” means a committee established in accordance with the National Academies' Guidelines for Human Embryonic Stem Cell Research, as amended from time to time.
(2)“Cloning of a human being” means inducing or permitting a replicate of a living human being's complete set of genetic material to develop after gastrulation commences.
(3)“Gastrulation” means the process immediately following the blastula state when the hollow ball of cells representing the early embryo undergoes a complex and coordinated series of movements that results in the formation of the three primary germ layers, the ectoderm, mesoderm and endoderm.
(4)“Embryonic stem cells” means cells created thr
Free access — add to your briefcase to read the full text and ask questions with AI
Connecticut § 32-41jj ((Formerly Sec. 19a-32d). Regenerative medicine research: Definitions. Prohibition on human cloning. Disposition of embryos or embryonic stem cells following infertility treatment. Written consent required for donations. Embryonic stem cell research authorized. Penalties.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.
Legislative History
(P.A. 05-149, S. 1; 05-272, S. 36; P.A. 08-80, S. 1; P.A. 13-258, S. 68; P.A. 14-98, S. 32; P.A. 15-222, S. 1; 15-242, S. 4.) History: P.A. 05-149 effective June 15, 2005; P.A. 05-272 added Subsec. (f) establishing penalty for conducting research involving embryonic stem cells in violation of Subsec. (d)(2), effective July 13, 2005; P.A. 08-80 amended Subsec. (a)(1) by substituting definition of “embryonic stem cell research oversight committee” for definition of “institutional review committee”, amended Subsec. (c)(3) by specifying that consent obtained conform to the National Academies' Guidelines for Human Embryonic Stem Cell Research, amended Subsec. (d)(3) by restructuring existing provisions and adding provision re embryonic stem cells derived outside the state shall have been acceptably derived as provided in the National Academies' Guidelines for Human Embryonic Stem Cell Research, deleted former Subsec. (d)(4) and (5) re general research program and protocol, and added new Subsec. (d)(4) re oversight of all activities involving embryonic stem cells by an embryonic stem cell research oversight committee; P.A. 13-258 amended Subsecs. (c)(4) and (f) to substitute provisions re class D felony for provisions re imprisonment of not more than 5 years; P.A. 14-98 amended Subsec. (a) by replacing “embryonic or human adult stem cell” with “regenerative medicine” in Subdiv. (6) and adding Subdiv. (7) defining “regenerative medicine”; Sec. 19a-32d transferred to Sec. 32-41jj in 2015; P.A. 15-222 amended Subsec. (a) by adding Subdiv. (8) defining “financial assistance”, effective July 1, 2015; P.A. 15-242 amended Subsec. (d)(3) by deleting provision re person to provide documentation to commissioner, deleted former Subsec. (e) re regulations and redesignated existing Subsec. (f) as Subsec. (e).
Nearby Sections
15
§ 32-1
Members.§ 32-101
Termination of council.§ 32-11a
Connecticut Innovations, Incorporated. Successor agency to Connecticut Development Authority.§ 32-11b
Definitions.§ 32-11e
Corporation subsidiaries.§ 32-11g
Connecticut Innovations, Incorporated. Successor to Connecticut Brownfields Redevelopment Authority.§ 32-140
Definitions.§ 32-15
Applications for insurance.